Multicenter trial of the therapeutic effect of a newly developed antiplatelet agent, satigrel, on biopsy-proven chronic rejection after kidney transplantation.
Teraoka
S
S
Kidney Center, Tokyo Women's Medical College, Japan.
Ota
K
K
Tanabe
K
K
Takahashi
K
K
Toma
H
H
Yasumura
T
T
Yoshimura
N
N
Oka
T
T
Takahara
S
S
Okuyama
A
A
Haba
T
T
Uchida
K
K
Sugiyama
S
S
Ohshima
S
S
Sato
T
T
Okazaki
H
H
Morozumi
K
K
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000328:Adult; D001707:Biopsy, Needle; D001806:Blood Urea Nitrogen; D003404:Creatinine / Q000378:metabolism; D005229:Fatty Acids, Monounsaturated / Q000627:therapeutic use*; D005260:Female; D006084:Graft Rejection / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D013929:Thromboxane B2 / Q000097:blood; D013997:Time Factors
D005229:Fatty Acids, Monounsaturated; D010975:Platelet Aggregation Inhibitors; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D003404:Creatinine; C054678:Satigrel